公司研究医药与健康护理医疗保健设备与用品
新产业（300832）公司跟踪报告
新产业：国内外共振的发光领先企业
 我们认为新产业是少有的实现国内外共振的医药公司，国内市场集采预计带
来2-3 年国产替代加速，海外市场新产业已成为国产发光龙头企业。
 深耕海外业务超10 年，海外业务收入复合增速约39%。新产业于1995 年成
立，主要从事研发、生产及销售系列全自动化学发光免疫分析仪器及配套试
剂。公司已深耕海外10 余年，2012 年公司海外收入超3600 万元，2014 年海
外收入102 亿元，2022 年公司海外收入969 亿元，2012 年-2022 年海外收入
CAGR 约39%。截至2023 年上半年，公司海外收入占比35%。
 全球空间：全球免疫诊断市场规模22 年约7070 亿美元，我们判断新产业仍
有较大收入空间。根据艾瑞咨询数据，2022 年全球体外诊断市场规模预计达
970 亿美元。其中免疫诊断市场约占30%，对应市场规模约291 亿美元，新
产业市占率仅15%。同时，对比全球IVD 龙头2022 年财年体外诊断板块收入，
罗氏19277 亿美元，雅培16584 亿美元，丹纳赫10849 亿美元，西门子医
疗5971 亿美元，我们判断公司未来仍有较大收入空间。
 成本优势：公司采取国内生产供应海外的经营模式获得成本优势，试剂毛利
率接近90%，试剂原料自给率70%。新产业在国内原料端，已经实现核心抗
原、抗体自给率超过70%。新产业国内生产供应海外的经营模式使得公司能
够享受国内的生产成本优势，从EBITDA收入比例来看，新产业能够维持近
50%的水平，而罗氏诊断和西门子医疗的诊断业务板块仅能保持2030%水平。
2022 年公司体外诊断试剂毛利率89%，在国产厂商中亦处于较高水平。
 工程师红利：公司新机器试剂推出速度较外资更快，最早推出600 速高速机。
截至2023 年上半年，公司可提供10 个型号的全自动化学发光免疫分析仪，
涵盖低、中、高速的不同机型，以满足不同类型客户的产品需求，2018 年发
布的MAGLUMI X8 为全球首台600TH 超高速全自动化学发光免疫分析仪。从
诊断项目上看，截至2021 年上半年，海外体外诊断巨头如罗氏、西门子获批
检测项目数在100 项左右，而新产业达141 项。
 盈利预测与投资建议。我们预计公司23-25 年EPS 分别为207、268、347
元（原为210、267、345 元），归母净利润增速为222%、298%、296%，
参考可比公司估值，考虑公司所处医疗器械板块的高景气度和领先地位，我
们给予公司2024 年35 倍PE（原为2023 年33x），对应目标价9382 元股
（35%），给予优于大市评级。
 风险提示：海外拓展不及预期，集采降价风险，股价波动风险，市场风险等。
(-)YoY(%)
(-)YoY(%)
全面摊薄EPS(元)
资料来源：公司年报（2021-2022），HTI
备注：净利润为归属母公司所有者的净利润
公司研究新产业（300832）2
化学发光出海龙头，借力本土成本研发优势海外突破  5
剃须刀刀片商业模式进行海外拓展，收入增长确定性较高  6
国内生产具备成本优势，研发端具备工程师红利 6
为什么推荐关注新产业的出海？——九个重点问题的回答  7
盈利预测与投资建议  9
风险提示  9
财务报表分析和预测  10
公司研究新产业（300832）3
新产业总收入归母净利润及YOY  5
新产业分区域收入拆分 5
2017 年头部四家公司占据全球IVD 市场超过50%的市场份额  5
公司海外化学发光仪器销量（台）及中大型机占比  6
公司海外化学发光试剂销售收入（万元）  6
公司与外资IVD 企业EBITDA Margin 比较  7
西门子医疗人均薪酬约为新产业的34 倍(万美元)  7
2021 年上半年主要化学发光企业免疫检测项目数量(个)  7
为什么推荐关注新产业的出海？——九个重点问题的回答  8
公司研究新产业（300832）4
业务拆分表  9
可比公司估值比较  9
公司研究新产业（300832）5
1 化学发光出海龙头，借力本土成本研发优势海外突破
深耕海外业务超10 年，12-23 年海外业务收入增速约39%。新产业于1995 年成立，
主要从事研发、生产及销售系列全自动化学发光免疫分析仪器及配套试剂。公司于2010
年成功研发并推出了国产第一台全自动化学发光免疫分析仪，截至2023 年上半年，公司
各型号全自动化学发光免疫分析仪全球累计销售装机超过29500 台，已覆盖国内医疗终
端超9100 家，并已销售至海外151 个国家和地区。公司深耕海外10 余年，2012 年公司
海外收入超3600 万元，2014 年海外收入102 亿元，2022 年公司海外收入969 亿元，
2012 年-2022 年海外收入CAGR 约39%。
图1 新产业总收入归母净利润及YOY
资料来源：Wind，HTI
图2 新产业分区域收入拆分
资料来源：Wind，HTI
全球免疫诊断市场规模22 年约970 亿美元，对比全球IVD 龙头规模我们判断公司
未来仍有较大收入空间。根据Evaluate Medtech 数据，2017 年罗氏、雅培、丹纳赫及西
门子四家公司占据国际IVD 市场超过50%的市场份额，前10 名企业占据超过70%的市场
份额，全球IVD 巨头优势较为明显。
根据艾瑞咨询数据，2022 年全球体外诊断市场规模预计达970 亿美元。其中免疫诊
断市场约占30%，测算得全球免疫诊断市场规模约291 亿美元。新产业2022 年总收入
437 亿美元，对应市占率约15%。同时，对比全球IVD 龙头2022 年财年体外诊断板块
收入，罗氏19277 亿美元，雅培16584 亿美元，丹纳赫10849 亿美元，西门子医疗5971
亿美元，我们判断公司未来仍有较大收入空间。
图3 2017 年头部四家公司占据全球IVD 市场超过50%的市场份额
Thermo Fisher Scientific
Ortho-Clinical Diagnostics
资料来源：Evaluate Medtech、HTI
公司研究新产业（300832）6
11 剃须刀刀片商业模式进行海外拓展，收入增长确定性较高
公司采取剃须刀刀片的商业模式，通过装机试剂的模式进行海外拓展，公司海外
中大型机装机比例提升，带动试剂增长加速，确定性较高。
海外中大型机装机占比快速提升，为中长期单产提高奠定基础。2023 年上半年，
公司海外市场共计销售全自动化学发光仪器2271 台，中大型发光仪器销量占比提升至
5473%，较上年同期增长2028 个百分点；随着海外市场装机数量的快速增长及中大型
机占比的持续提升，为后续海外试剂业务的增长奠定了坚实基础。2023 年上半年，公
司海外实现主营业务收入649 亿元，同比增长3155%，其中海外试剂业务收入同比增
长4210%，海外仪器类收入同比增长2261%；反映了良好的增长趋势。我们认为，公
司海外仪器销售结构的持续优化反映了公司正逐步突破海外中大型终端，有望带动中长
图4 公司海外化学发光仪器销量（台）及中大型机占比
化学发光免疫分析仪器销量(台，左轴)
中大型机销量占比(%，右轴)
资料来源：新产业招股书，新产业2020-2022 年年报，新产业2023 年8 月
25 日投资者关系活动记录表，HTI
图5 公司海外化学发光试剂销售收入（万元）
化学发光试剂海外销售额（万元，左轴）
同比增长(%，右轴)
资料来源：新产业招股书，新产业2020-2022 年年报，新产业2023 年8 月
25 日投资者关系活动记录表，HTI
12 国内生产具备成本优势，研发端具备工程师红利
公司采取国内生产供应海外的经营模式获得成本优势，试剂毛利率接近90%，试剂
原料自给率70%。从EBITDA收入比例来看，新产业能够维持近50%的水平，而罗氏诊
断和西门子医疗的诊断业务板块仅能保持2030%水平。同时借助国内工程师红利，公
司新机器试剂推出速度较外资更快，最早推出600 速高速机。
新产业所有产品均为在国内完成生产后发出，且截至23 年10 月公司暂无在海外市
场设立生产基地的计划，主要原因有两点：1、国内制造业高度发达，成本控制相较海
外更具有优势。公司在国内原料端，已经实现核心抗原、抗体自给率超过70%；在生产
工艺上，公司定制开发了国内首条全自动化试剂灌装生产线，大大节约了时间成本和人
力成本；2、公司试剂产品有效期大部分为12 个月，根据公司需要可以在多个重点国家
及地区自建仓库，暂时没有出现因为产品供货问题影响销售的情况。
新产业国内生产供应海外的经营模式使得公司能够享受国内的生产成本优势，从
EBITDA收入比例来看，新产业基本能够维持超50%的水平，而罗氏诊断和西门子医疗
的诊断业务板块仅能保持2030%水平。
公司研究新产业（300832）7
图6 公司与外资IVD 企业EBITDA Margin 比较
资料来源：Bloomberg，Wind，HTI
结合国内工程师红利，新产业劳动力资源优势显著，公司设备及试剂项目迭代迅速。
依托国内劳动力资源优势，新产业能够以更低成本推动研发生产。公司2019 至2022
年每年人均薪酬在25 至3 万美元水平，而西门子医疗人均薪酬在10 万美元水平，是
截至2023 年上半年，新产业可提供10 个型号的全自动化学发光免疫分析仪，涵盖
低、中、高速的不同机型，以满足不同类型客户的产品需求，2018 年发布的MAGLUMI X8
为全球首台600TH 超高速全自动化学发光免疫分析仪，最高可达2400TH，2021 年3
月份推出MAGLUMI X3，2022 年10 月底新推出MAGLUMI X6 化学发光免疫分析仪，检
测速度高达450 测试小时，拥有超高的性价比优势。从诊断项目上看，截至2021 年上
半年，海外体外诊断巨头如罗氏、西门子获批检测项目数在100 项左右，而新产业达
图7 西门子医疗人均薪酬约为新产业的34 倍(万美元)
资料来源：Bloomberg，Wind，HTI
图8 2021 年上半年主要化学发光企业免疫检测项目数量(个)
资料来源：菲鹏生物招股书(注册稿)援引NMPA 及各公司官网，HTI
2 为什么推荐关注新产业的出海？——九个重点问题的回
我们认为新产业是少有的实现国内外共振的医药公司，国内市场集采预计带来2-3
年国产替代加速，并且在海外市场新产业已成为国产发光龙头企业。
公司研究新产业（300832）8
图9 为什么推荐关注新产业的出海？——九个重点问题的回答
资料来源：新产业2020-2022 年年报，新产业2023 年半年报，新产业招股书，新产业2022 年4 月22 日-26 日投资者关系活动记录表，新产业2023 年8
月25 日投资者关系活动记录表，新产业2023 年10 月27 日-10 月31 日投资者关系活动记录表，新产业官网，菲鹏生物招股书(注册稿)援引NMPA 及各
公司官网，Bloomberg，Wind，HTI
公司研究新产业（300832）9
3 盈利预测与投资建议
我们预计公司23-25 年EPS 分别为207、268、347 元，归母净利润增速为222%、
298%、296%，参考可比公司估值，考虑公司所处医疗器械板块的高景气度和领先地位，
我们给予公司2024 年35 倍PE，对应目标价9382 元股，给予优于大市评级。
资料来源：Wind，HTI
表 2 可比公司估值比较
资料来源：Wind，HTI，备注：收盘价日期20240308，可比公司EPS 为Wind 一致预期
海外拓展不及预期，集采降价风险，股价波动风险，市场风险等。
公司研究新产业（300832）10
资产负债表（百万元）
现金流量表（百万元）
备注：（1）表中计算估值指标的收盘价日期为03 月08 日；（2）以上各表均为简表
资料来源：公司年报（2022），HTI
公司研究新产业（300832）11
APPENDIX 1
Investment Highlights
approximately 39% in overseas revenue Established in 1995 Snibe specializes in developing producing and selling fully
automated chemiluminescence immunoassay systems and reagents Since 2012 overseas revenue grew from RMB 36 million to
RMB 102 million in 2014 reaching RMB 969 million in 2022 with a CAGR of about 39% from 2012 to 2022 As of the first half of
2023 overseas sales accounted for 35% of total revenue
Global Market The global immune diagnostics market was valued at approximately 707 billion in 2022 with Snibe having
significant room for revenue growth According to iResearch the global in vitro diagnostics (IVD) market is expected to reach 97
billion in 2022 with immune diagnostics accounting for 30% or about 291 billion Snibes market share is only 15% Compared
to global IVD leaders 2022 revenues—Roche at 19277 billion Abbott at 16584 billion Danaher at 10849 billion and
Siemens at 5971 billion—Snibe has substantial potential for growth
Cost Advantage Snibes domestic production for overseas supply grants cost benefits with reagent GPM nearing 90% and
sectors which only maintain 20-30% In 2022 Snibes IVD reagent GPM was 89% one of the highest among domestic
manufacturers
Engineer Dividend Snibe releases new machinesreagents faster than foreign-funded enterprises being the first to launch a
high-speed 600TH machine By mid-2023 Snibe offered 10 models of fully automated chemiluminescence immunoassay
analyzers covering low medium and high speeds to meet diverse customer needs The MAGLUMI X8 released in 2018 was the
worlds first ultra-high-speed 600TH analyzer In terms of diagnostic items Snibe had 141 approved tests by mid-2021
surpassing the approximately 100 tests approved for overseas IVD giants like Roche and Siemens
Earnings Forecast and Investment Advice We predict Snibes EPS for 2023-2025 to be RMB 207 268 and 347 with net profit
the high prosperity of the Medical equipment sector and Snibes leading position we give a 2024 PE of 35 times with a target
price of RMB 9382 per share and an Outperform rating
Risk Warning Risks include weaker than expected overseas expansion centralized procurement price reductions stock price
volatility and market risks
IMPORTANT DISCLOSURES
This research report is distributed by Haitong International a global brand name for the equity research teams of Haitong International Research Limited (HTIRL) Haitong Securities India Private
Limited (HSIPL) Haitong International Japan KK (HTIJKK) Haitong International Securities Company Limited (HTISCL) and any other members within the Haitong International Securities Group
of Companies (HTISG) each authorized to engage in securities activities in its respective jurisdiction
我， 孟科含，在此保证（i）本研究报告中的意见准确反映了我们对本研究中提及的任何或所有目标公司或上市公司的个人观点，并且（ii）我的报酬中没有任何部分与本研究报告中表
whom I have already notified of this will not deal in or trade any securities in respect of the issuer that I review within 3 business days after the research report is published
利益冲突披露Conflict of Interest Disclosures
海通国际及其某些关联公司可从事投资银行业务和或对本研究中的特定股票或公司进行做市或持有自营头寸。就本研究报告而言，以下是有关该等关系的披露事项（以下披露不能保
海通期货青岛海洋创新产业投资基金有限公司海通期货通合共盈FOF 三十六期单一资产管理计划金华中开院高新产业发展合伙企业（有限合伙）青岛海洋创新产业投资基金有
限公司威海市鲲翎服务贸易创新产业投资基金合伙企业（有限合伙）中山市长青新产业有限公司青岛海洋创新产业投资基金有限公司威海市鲲翎服务贸易创新产业投资基金合伙企业
海通期货青岛海洋创新产业投资基金有限公司海通期货通合共盈FOF 三十六期单一资产管理计划金华中开院高新产业发展合伙企业（有限合伙）青岛海洋创新产业投资基金有
限公司威海市鲲翎服务贸易创新产业投资基金合伙企业（有限合伙）中山市长青新产业有限公司青岛海洋创新产业投资基金有限公司威海市鲲翎服务贸易创新产业投资基金合伙企业
（有限合伙） and 中山市长青新产业有限公司 iswas a client of Haitong currently or within the past 12 months The client has been provided for non-investment-banking securities-related
评级定义（从2020 年7 月1 日开始执行）：
海通国际（以下简称HTI）采用相对评级系统来为投资者推荐我们覆盖的公
司：优于大市、中性或弱于大市。投资者应仔细阅读HTI 的评级定义。并且HTI
基于各自情况（比如投资者的现有持仓）以及其他因素。
优于大市，未来12-18 个月内预期相对基准指数涨幅在10%以上，基准定义如
中性，未来12-18 个月内预期相对基准指数变化不大，基准定义如下。根据
FINRANYSE 的评级分布规则，我们会将中性评级划入持有这一类别。
弱于大市，未来12-18 个月内预期相对基准指数跌幅在10%以上，基准定义如
各地股票基准指数：日本  TOPIX 韩国  KOSPI 台湾  TAIEX 印度  Nifty100 美
国  SP500 其他所有中国概念股  MSCI China
Ratings Definitions (from 1 Jul 2020)
Haitong International uses a relative rating system using Outperform
investors Investors should carefully read the definitions of all ratings used
in Haitong International Research In addition since Haitong International
views investors should carefully read Haitong International Research in its
entirety and not infer the contents from the rating alone In any case
评级分布Rating Distribution
ratings (or research) should not be used or relied upon as investment
advice An investors decision to buy or sell a stock should depend on
individual circumstances (such as the investors existing holdings) and other
considerations
Analyst Stock Ratings
Outperform The stocks total return over the next 12-18 months is
expected to exceed the return of its relevant broad market benchmark as
indicated below
Neutral The stocks total return over the next 12-18 months is expected to
be in line with the return of its relevant broad market benchmark as
indicated below For purposes only of FINRANYSE ratings distribution
rules our Neutral rating falls into a hold rating category
Underperform The stocks total return over the next 12-18 months is
expected to be below the return of its relevant broad market benchmark
as indicated below
Benchmarks for each stocks listed region are as follows Japan  TOPIX
Korea  KOSPI Taiwan  TAIEX India  Nifty100 US  SP500 for all other
China-concept stocks  MSCI China
截至2023 年12 月31 日海通国际股票研究评级分布
在每个评级类别里投资银行客户所占的百分比。
上述分布中的买入，中性和卖出分别对应我们当前优于大市，中性和落后大市评级。
只有根据FINRANYSE 的评级分布规则，我们才将中性评级划入持有这一类别。请注意在上表中不包含非评级的股票。
此前的评级系统定义（直至2020 年6 月30 日）：
买入，未来12-18 个月内预期相对基准指数涨幅在10%以上，基准定义如下
中性，未来12-18 个月内预期相对基准指数变化不大，基准定义如下。根据FINRANYSE 的评级分布规则，我们会将中性评级划入持有这一类别。
卖出，未来12-18 个月内预期相对基准指数跌幅在10%以上，基准定义如下
各地股票基准指数：日本  TOPIX 韩国  KOSPI 台湾  TAIEX 印度  Nifty100 其他所有中国概念股  MSCI China
Haitong International Equity Research Ratings Distribution as of December 31 2023
HTI Equity Research Coverage
IB clients
Percentage of investment banking clients in each rating category
BUY Neutral and SELL in the above distribution correspond to our current ratings of Outperform Neutral and Underperform
For purposes only of FINRANYSE ratings distribution rules our Neutral rating falls into a hold rating category Please note that stocks with an NR designation are not included in the table above
Previous rating system definitions (until 30 Jun 2020)
BUY The stocks total return over the next 12-18 months is expected to exceed the return of its relevant broad market benchmark as indicated below
NEUTRAL The stocks total return over the next 12-18 months is expected to be in line with the return of its relevant broad market benchmark as indicated below For purposes
only of FINRANYSE ratings distribution rules our Neutral rating falls into a hold rating category
SELL The stocks total return over the next 12-18 months is expected to be below the return of its relevant broad market benchmark as indicated below
Benchmarks for each stocks listed region are as follows Japan  TOPIX Korea  KOSPI Taiwan  TAIEX India  Nifty100 for all other China-concept stocks  MSCI China
海通国际非评级研究：海通国际发布计量、筛选或短篇报告，并在报告中根据估值和其他指标对股票进行排名，或者基于可能的估值倍数提出建议价格。这种排名或建议价格并非为
了进行股票评级、提出目标价格或进行基本面估值，而仅供参考使用。
Haitong International Non-Rated Research  Haitong International publishes quantitative screening or short reports which may rank stocks according to valuation and other metrics or may suggest
prices based on possible valuation multiples Such rankings or suggested prices do not purport to be stock ratings or target prices or fundamental values and are for information only
Haitong International Coverage of A-Shares  Haitong International may cover and rate A-Shares that are subject to the Hong Kong Stock Connect scheme with Shanghai and Shenzhen Haitong
system employed by HS differs from that used by HTI and as a result there may be a difference in the HTI and HS ratings for the same A-share stocks
股团队自下而上的研究。海通国际每季对Q100 指数成分作出复审。
Haitong International Quality 100 A-share (Q100) Index  HTIs Q100 Index is a quant product that consists of 100 of the highest-quality A-shares under coverage at HS in Shanghai These stocks are
盟浪义利（FIN-ESG）数据通免责声明条款：在使用盟浪义利（FIN-ESG）数据之前，请务必仔细阅读本条款并同意本声明：
第一条 义利（FIN-ESG）数据系由盟浪可持续数字科技有限责任公司（以下简称本公司）基于合法取得的公开信息评估而成，本公司对信息的准确性及完整性不作任何保证。对公司
的评估结果仅供参考，并不构成对任何个人或机构投资建议，也不能作为任何个人或机构购买、出售或持有相关金融产品的依据。本公司不对任何个人或机构投资者因使用本数据表
述的评估结果造成的任何直接或间接损失负责。
第二条 盟浪并不因收到此评估数据而将收件人视为客户，收件人使用此数据时应根据自身实际情况作出自我独立判断。本数据所载内容反映的是盟浪在最初发布本数据日期当日的判
断，盟浪有权在不发出通知的情况下更新、修订与发出其他与本数据所载内容不一致或有不同结论的数据。除非另行说明，本数据（如财务业绩数据等）仅代表过往表现，过往的业
绩表现不作为日后回报的预测。
第三条 本数据版权归本公司所有，本公司依法保留各项权利。未经本公司事先书面许可授权，任何个人或机构不得将本数据中的评估结果用于任何营利性目的，不得对本数据进行修
改、复制、编译、汇编、再次编辑、改编、删减、缩写、节选、发行、出租、展览、表演、放映、广播、信息网络传播、摄制、增加图标及说明等，否则因此给盟浪或其他第三方造
成损失的，由用户承担相应的赔偿责任，盟浪不承担责任。
第四条 如本免责声明未约定，而盟浪网站平台载明的其他协议内容（如盟浪网站用户注册协议盟浪网用户服务（含认证）协议盟浪网隐私政策等）有约定的，则按其他
协议的约定执行；若本免责声明与其他协议约定存在冲突或不一致的，则以本免责声明约定为准。
SusallWave FIN-ESG Data Service Disclaimer Please read these terms and conditions below carefully and confirm your agreement and acceptance with these terms before using SusallWave FIN-
ESG Data Service
FIN-ESG Data is produced by SusallWave Digital Technology Co Ltd (In short SusallWave)s assessment based on legal publicly accessible information SusallWave shall not be responsible
selling or holding any relative financial products We will not be liable for any direct or indirect loss of any individual or institution as a result of using SusallWave FIN-ESG Data
SusallWave do not consider recipients as customers for receiving these data When using the data recipients shall make your own independent judgment according to your practical individual
status The contents of the data reflect the judgment of us only on the release day We have right to update and amend the data and release other data that contains inconsistent contents or
different conclusions without notification Unless expressly stated the data (eg financial performance data) represents past performance only and the past performance cannot be viewed as the
prediction of future return
abbreviation excerpts issuance rent exhibition performance projection broadcast information network transmission shooting adding icons and instructions If any loss of SusallWave or any
If any term is not contained in this disclaimer but written in other agreements on our website (eg User Registration Protocol of SusallWave Website User Service (including authentication)
Agreement of SusallWave Website Privacy Policy of Susallwave Website) it should be executed according to other agreements If there is any difference between this disclaim and other agreements
this disclaimer shall be applied
行，包括制作及发布涵盖BSE Limited（BSE）和National Stock Exchange of India Limited（NSE）上市公司（统称为印度交易所）的研究报告。HTSIPL 于2016 年12 月22 日被收购
声明或保证。本文件中所有观点均截至本报告日期，如有更改，恕不另行通知。本文件仅供参考使用。文件中提及的任何公司或其股票的说明并非意图展示完整的内容，本文件并非
可能会对投资产生不利影响。过去的表现并不一定代表将来的结果。某些特定交易，包括设计金融衍生工具的，有产生重大风险的可能性，因此并不适合所有的投资者。您还应认识到
其他方面的专业顾问，以期在投资之前评估该项建议是否适合于您。若由于使用本文件所载的材料而产生任何直接或间接的损失，HTISG 及其董事、雇员或代理人对此均不承担任何责
HTISG 的销售员、交易员和其他专业人士均可向HTISG 的相关客户和公司提供与本文件所述意见相反的口头或书面市场评论意见或交易策略。HTISG 可做出与本文件所述建议或意见不
一致的投资决策。但HTIRL 没有义务来确保本文件的收件人了解到该等交易决定、思路或建议。
For research reports on non-Indian securities The research report is issued by Haitong International Research Limited (HTIRL) a wholly owned subsidiary of Haitong International Securities Group
Limited (HTISGL) and a licensed corporation to carry on Type 4 regulated activity (advising on securities) for the purpose of the Securities and Futures Ordinance (Cap 571) of Hong Kong with the
assistance of Haitong International (Japan) KK (HTIJKK) a wholly owned subsidiary of HTISGL and which is regulated as an Investment Adviser by the Kanto Finance Bureau of Japan
registered Stock Broker Merchant Banker and Research Analyst that inter alia produces and distributes research reports covering listed entities on the BSE Limited (BSE) and the National Stock
Exchange of India Limited (NSE) (collectively referred to as Indian Exchanges) HSIPL was acquired and became part of the Haitong International Securities Group of Companies (HTISG) on 22
December 2016
All the research reports are globally branded under the name Haitong International and approved for distribution by Haitong International Securities Company Limited (HTISCL) andor any other
members within HTISG in their respective jurisdictions
referred to in this research report may not be eligible for purchase or sale in some jurisdictions If an investment product is denominated in a currency other than an investors home currency a
change in exchange rates may adversely affect the investment Past performance is not necessarily indicative of future results Certain transactions including those involving derivatives give rise to
your unique financial circumstances such as your financial situation and risk appetite You must therefore analyze and should where applicable consult your own legal tax accounting financial
for any direct or consequential loss arising from any use of the materials contained in this research report
HTISG and our affiliates officers directors and employees excluding the analysts responsible for the content of this document will from time to time have long or short positions in act as principal
to the attention of any recipient of this research report
with respect to Research
Non US Analyst Disclosure  The HTI analyst(s) listed on the cover of this Research is (are) not registered or qualified as a  research analyst with FINRA and are not subject to US FINRA Rule 2241
期货事务监察委员会的审查。您不应仅根据本研究报告中所载的信息做出投资决定。本研究报告的收件人就研究报告中产生或与之相关的任何事宜请联系HTISCL 销售人员。
美国投资者的通知事项：本研究报告由HTIRL，HSIPL 或HTIJKK 编写。 HTIRL，HSIPL，HTIJKK 以及任何非HTISG 美国联营公司，均未在美国注册，因此不受美国关于研究报告编制和研
资者（US Institutional Investors）。在向美国机构投资者分发研究报告时，Haitong International Securities (USA) Inc （HTI USA） 将对报告的内容负责。任何收到本研究报告的美国
351-6050。 HTI USA 是在美国于US Securities and Exchange Commission（SEC）注册的经纪商，也是Financial Industry Regulatory Authority Inc（FINRA）的成员。 HTIUSA 不负责编写
Haitong International Securities (USA) Inc
340 Madison Avenue 12th Floor
New York NY 10173
DISTRIBUTION AND REGIONAL NOTICES
Except as otherwise indicated below any Recipient wishing to discuss this research report or effect any transaction in any security discussed in HTIs research should contact the Haitong International
salesperson in their own country or region
Notice to Hong Kong investors The research report is distributed by Haitong International Securities Company Limited (HTISCL) which is a licensed corporation to carry on Type 1 regulated activity
(dealing in securities) in Hong Kong This research report does not constitute a solicitation or an offer of securities or an invitation to the public within the meaning of the SFO This research report
is only to be circulated to Professional Investors as defined in the SFO This research report has not been reviewed by the Securities and Futures Commission You should not make investment
decisions solely on the basis of the information contained in this research report Recipients of this research report are to contact HTISCL salespersons in respect of any matters arising from or in
connection with the research report
Notice to US investors As described above this research report was prepared by HTIRL HSIPL or HTIJKK Neither HTIRL HSIPL HTIJKK nor any of the non US HTISG affiliates is registered in the
United States and therefore is not subject to US rules regarding the preparation of research reports and the independence of research analysts  This research report is provided for distribution to
major US institutional investors and US institutional investors in reliance on the exemption from registration provided by Rule 15a-6 of the US Securities Exchange Act of 1934 as amended
When distributing research reports to US institutional investors HTI USA will accept the responsibilities for the content of the reports  Any US recipient of this research report wishing to effect
any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Haitong International Securities (USA)
Inc (HTI USA) located at 340 Madison Avenue 12th Floor New York NY 10173 USA telephone (212) 351 6050  HTI USA is a broker-dealer registered in the US with the US Securities and
Exchange Commission (the SEC) and a member of the Financial Industry Regulatory Authority Inc (FINRA)  HTI USA is not responsible for the preparation of this research report nor for the
analysis contained therein  Under no circumstances should any US recipient of this research report contact the analyst directly or effect any transaction to buy or sell securities or related financial
instruments directly through HSIPL HTIRL or HTIJKK  The HSIPL HTIRL or HTIJKK analyst(s) whose name appears in this research report is not registered or qualified as a research analyst with FINRA
in any non-US securities or related financial instruments (including ADRs) discussed in this research report may present certain risks  The securities of non-US issuers may not be registered with
financial instruments All inquiries by US recipients should be directed to
Haitong International Securities (USA) Inc
340 Madison Avenue 12th Floor
New York NY 10173
Attn  Sales Desk at (212) 351 6050
中华人民共和国的通知事项：在中华人民共和国（下称中国，就本报告目的而言，不包括香港特别行政区、澳门特别行政区和台湾）只有根据适用的中国法律法规而收到该材料的人
103 Registration Requirements Exemptions and Ongoing Registrant Obligations（NI 31-103）的规定得到国际交易商豁免（International Dealer Exemption ）的交易商，位于艾伯塔
National Instrument 45-106 Prospectus Exemptions 第11 节或者Securities Act (Ontario)第733(1)节所规定的认可投资者（Accredited Investor），或者在适用情况下National
Instrument 31-103 第11 节所规定的许可投资者（Permitted Investor）。
新加坡投资者的通知事项：本研究报告由Haitong International Securities (Singapore) Pte Ltd（HTISSPL）公司注册编号201311400G 于新加坡提供。HTISSPL 是符合财务顾问法（第
题，本研究报告的收件人应通过以下信息与HTISSPL 联系：
Haitong International Securities (Singapore) Pte Ltd
50 Raffles Place 33-03 Singapore Land Tower Singapore 048623
（1）条，第17-11（1）条的执行及相关条款）。
相关的投资行为只面对此类专业客户。没有投资经验或相关投资经验的客户不得依赖本报告。Haitong International Securities Company Limited 的分支机构的净长期或短期金融权益可能
超过本研究报告中提及的实体已发行股本总额的05。特别提醒有些英文报告有可能此前已经通过中文或其它语言完成发布。
澳大利亚投资者的通知事项：Haitong International Securities (Singapore) Pte Ltd Haitong International Securities Company Limited 和Haitong International Securities (UK) Limited 分别根据澳
等法律与在澳大利亚所适用的法律存在差异。
发布，包括制作及发布涵盖BSE Limited（BSE）和National Stock Exchange of India Limited（NSE）（统称为印度交易所）研究报告。
研究机构名称 Haitong Securities India Private Limited
841 Senapati Bapat Marg Elphinstone Road Mumbai 400 013 India
请注意，SEBI 授予的注册和 NISM 的认证并不保证中介的表现或为投资者提供任何回报保证。
本项研究仅供收件人使用，未经海通国际的书面同意不得予以复制和再次分发。
Peoples Republic of China (PRC) In the PRC the research report is directed for the sole use of those who receive the research report in accordance with the applicable PRC laws and regulations
Further the information on the research report does not constitute production and business activities in the PRC under relevant PRC laws This research report does not constitute a public offer
of the security whether by sale or subscription in the PRC Further no legal or natural persons of the PRC may directly or indirectly purchase any of the security or any beneficial interest therein
these restrictions
Notice to Canadian Investors Under no circumstances is this research report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada
Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and
only by Haitong International Securities (USA) Inc a dealer relying on the international dealer exemption under National Instrument 31-103 Registration Requirements Exemptions and Ongoing
Registrant Obligations (NI 31-103) in Alberta British Columbia Ontario and Quebec This research report is not and under no circumstances should be construed as a prospectus an offering
research report the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence Upon receipt of this research report each
Canadian recipient will be deemed to have represented that the investor is an accredited investor as such term is defined in section 11 of National Instrument 45-106 Prospectus Exemptions or
in Ontario in section 733(1) of the Securities Act (Ontario) as applicable and a permitted client as such term is defined in section 11 of NI 31-103 respectively
Notice to Singapore investors This research report is provided in Singapore by or through Haitong International Securities (Singapore) Pte Ltd (HTISSPL) Co Reg No 201311400G HTISSPL is an
Exempt Financial Adviser under the Financial Advisers Act (Cap 110) (FAA) to (a) advise on securities units in a collective investment scheme exchange-traded derivatives contracts and over-the-
counter derivatives contracts and (b) issue or promulgate research analyses or research reports on securities exchange-traded derivatives contracts and over-the-counter derivatives contracts This
research report is only provided to institutional investors within the meaning of Section 4A of the Securities and Futures Act (Cap 289) Recipients of this research report are to contact HTISSPL via
the details below in respect of any matters arising from or in connection with the research report
Haitong International Securities (Singapore) Pte Ltd
10 Collyer Quay 19-01 - 19-05 Ocean Financial Centre Singapore 049315
Telephone (65) 6536 1920
Notice to Japanese investors This research report is distributed by Haitong International Securities Company Limited and intended to be distributed to Financial Services Providers or Registered
Financial Institutions engaged in investment management (as defined in the Japan Financial Instruments and Exchange Act (FIEL) Art 61(1) Order for Enforcement of FIEL Art 17-11(1) and related
articles)
Notice to UK and European Union investors This research report is distributed by Haitong International Securities Company Limited This research is directed at persons having professional
experience in matters relating to investments Any investment or investment activity to which this research relates is available only to such persons or will be engaged in only with such persons
Persons who do not have professional experience in matters relating to investments should not rely on this research  Haitong International Securities Company Limiteds affiliates may have a net
long or short financial interest in excess of 05% of the total issued share capital of the entities mentioned in this research report  Please be aware that any report in English may have been published
previously in Chinese or another language
Notice to Australian investors The research report is distributed in Australia by Haitong International Securities (Singapore) Pte Ltd Haitong International Securities Company Limited and Haitong
International Securities (UK) Limited in reliance on ASIC Corporations (Repeal and Transitional) Instrument 2016396 which exempts those HTISG entities from the requirement to hold an Australian
financial services license under the Corporations Act 2001 in respect of the financial services it provides to wholesale clients in Australia  A copy of the ASIC Class Orders may be obtained at the
International Securities (UK) Limited are regulated under foreign laws and regulatory requirements which are different from the laws applying in Australia
Stock Broker Merchant Banker and Research Analyst that inter alia produces and distributes research reports covering listed entities on the BSE Limited (BSE) and the National Stock Exchange of
India Limited (NSE) (collectively referred to as Indian Exchanges)
Name of the entity Haitong Securities India Private Limited
SEBI Research Analyst Registration Number INH000002590
Address  1203A Floor 12A Tower 2A One World Center
841 Senapati Bapat Marg Elphinstone Road Mumbai 400 013 India
Please note that Registration granted by SEBI and Certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors
This research report is intended for the recipients only and may not be reproduced or redistributed without the written consent of an authorized signatory of HTISG
Copyright Haitong International Securities Group Limited 2019 All rights reserved